CliffBio
small molecule

SABRIL

VIGABATRIN

Loss of exclusivity—loss of exclusivity
CompanyLundbeck →See this company's full patent-cliff portfolio

Drug detail

Brand nameSABRIL
Active ingredientVIGABATRIN
Strength500MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusRX

More from Lundbeck

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.